Altria Group (MO) — Q3 2026 Earnings Preview
Key Points and Preview Table
| Factor | Details & What to Watch |
|---|---|
| Guidance Range (FY26 EPS) | $5.61–$5.72 (raised lower end in Q2; prior $5.56–$5.72) |
| Consensus FY26 EPS | $5.54 (rounded, from consensus; guidance above this) |
| Consensus Q3 2026 Revenue | $5,319M |
| Consensus Q3 2026 EPS | $1.50 |
| Q3 2025 Actual Revenue | $5,307M (rounded, as reported) |
| Q3 2025 Actual EPS (GAAP) | $1.44 (as reported) |
| Q3 2025 Adjusted EPS | $1.45 |
| Y/Y Comparable | Q3 2025 was a solid quarter with +3.6% adj. EPS growth |
| Guidance Phasing | H2 2026 expected to benefit more from import/export, duty drawback, and new launches (on! PLUS, Cowboy Cut) |
| Key KPIs to Watch | Adjusted diluted EPS, smokeable products OCI/margin, oral tobacco volumes and share, on! PLUS rollout, Basic/Cowboy Cut performance, duty drawback benefit realization, capital expenditures |
| Macro/Industry Factors | Moderation in cigarette volume declines, discount segment growth, consumer macro pressure, regulatory/enforcement actions in e-vapor |
Summary and Conclusions
- Altria enters Q3 2026 coming off a strong first half: H1 2026 adjusted diluted EPS grew +4.9% YoY, and the company raised the lower end of its full-year EPS guidance to $5.61–$5.72 (+3.5% to +5.5% YoY).
- Q3 2025 is a tough comparable: Last year’s Q3 saw adjusted EPS of $1.45 (+3.6% YoY), with resilient core tobacco businesses and margin expansion.
- Consensus for Q3 2026 is for revenue of ~$5,319M and EPS of $1.50, implying modest growth over last year’s Q3.
- Key factors for Q3 2026: Investors will focus on the realization of duty drawback benefits (import/export), continued moderation in cigarette volume declines, the national rollout and early performance of on! PLUS (including 12mg and new flavors), the impact of Cowboy Cut and Basic in the portfolio mix, and any signs of margin pressure or promotional intensity.
- Management has flagged: H2 2026 should see a more balanced benefit from export activity and related tax refunds, with incremental investments behind new product launches and marketing.
- Risks: Macro headwinds (inflation, gas prices), consumer trade-down, regulatory uncertainty, and competitive intensity in nicotine pouches.
Forward Guidance and Consensus
FY2026 Guidance vs. Consensus
| Metric | Company Guidance (as of Q2 2026) | Consensus Estimate | Notes |
|---|---|---|---|
| Adjusted Diluted EPS | $5.61–$5.72 | $5.54 | Guidance raised at Q2; consensus at low end |
| Capital Expenditures | $375M–$450M | Raised from $300M–$375M; reflects USSTC consolidation | |
| Adjusted Effective Tax Rate | 23.0% |
Q3 2026 Consensus vs. Prior Year Actuals
| Period | Revenue ($M) | GAAP EPS | Adjusted EPS | YoY Growth (Adj. EPS) |
|---|---|---|---|---|
| Q3 2026E | 5,319 | 1.50 | +3.4%* | |
| Q3 2025 | 5,307 | 1.44 | 1.45 | +3.6% |
*Consensus EPS vs. prior year actuals.
Q3 2025 Actuals (Restated Where Applicable)
| Metric | Q3 2025 Actual (as reported) |
|---|---|
| Net Revenues | $5,307M |
| Revenues net of excise taxes | $5,251M |
| Reported Diluted EPS | $1.41 |
| Adjusted Diluted EPS | $1.45 |
| Adjusted OCI Margin (Smokeable) | 64.4% |
| Adjusted OCI Margin (Oral) | 69.2% |
| Smokeable Volumes (YoY) | -8.2% |
| Oral Tobacco Volumes (YoY) | -9.6% |
| on! Shipment Volume | +0.7% YoY |
| on! Retail Share (Oral Cat.) | 8.7% |
What to Watch for in Q3 2026
1. Duty Drawback/Import-Export Activity
- Management expects a greater benefit from cigarette import/export activity in H2 2026, with more balanced benefit across Q3 and Q4.
- Q2 commentary: “...we continue to expect export volume and related tax refunds to be higher in the second half of the year, with a more balanced benefit across the third and fourth quarters.”
- Monitor: realization of these benefits in Q3, impact on margins and OCI.
2. Smokeable Products Segment
- Q2 2026: Adjusted OCI up +2.4%, margin 64.8%. Volume declines moderating (-3.2% reported, -4.5% adjusted).
- Watch for: further moderation in volume declines, price realization (noted +7% for Marlboro in Q2), mix impact from Basic and Cowboy Cut, and margin sustainability.
3. Oral Tobacco Products Segment
- Q2 2026: Adjusted OCI down -8.0%, margin 66.7%. on! shipment volume down -4.2% YoY (timing/inventory), but up +5.1% YTD.
- on! PLUS now in 120,000 stores (~90% of category volume). National launch of 12mg planned for Q3; new flavors in Q4.
- Watch for: acceleration in on! PLUS volumes, retail share gains, consumer feedback/retention, and impact of new flavors/strengths.
4. Portfolio Mix and Consumer Dynamics
- Discount segment continues to grow (Q2: +2.6pp YoY), driven by macro pressure.
- Basic’s targeted expansion (~35,000 stores) is capturing share without outsized impact to Marlboro.
- Cowboy Cut ramping up; management sees it as a tool to retain value-sensitive premium smokers.
- Watch for: any signs of cannibalization, margin impact, and overall PM USA share stability.
5. Regulatory and Competitive Environment
- FDA enforcement and regulatory clarity improving, especially for nicotine pouches and e-vapor.
- Helix expects faster PMTA pathway for on! PLUS line extensions.
- E-vapor illicit market still prevalent but showing signs of moderation.
- Watch for: updates on NJOY ACE re-entry, regulatory progress, and competitive responses.
6. Capital Allocation and Cash Returns
- $3.9B returned to shareholders in H1 2026; $665M left on buyback authorization.
- CapEx guidance raised to $375M–$450M for USSTC consolidation and innovation support.
Management Commentary and Tone
- Management remains confident in delivering on raised guidance, citing “steady, disciplined execution.”
- Cautious on consumer macro environment: “The consumer remains under pressure. Gas prices and inflation remain elevated, driven primarily by the uncertainty and the geopolitical climate that they are living in today.”
- Investments will continue behind on! PLUS, Cowboy Cut, and flavor/strength extensions.
- On smokeable strategy: “...maximize profitability over the long term... leverage RGM capabilities... provide value to those premium consumers who are under pressure.”
What Changed / Incremental Since Last Quarter
- Guidance range narrowed and lower end raised after strong H1.
- National expansion of on! PLUS 12mg in Q3; new flavors in Q4.
- CapEx guidance increased to reflect manufacturing consolidation.
- Early data shows on! PLUS is resonating with both loyal and competitive pouch consumers.
- Duty drawback/export benefit timing shifted to be more balanced across Q3/Q4.
Conclusion
Altria is coming off a strong H1 2026 with raised guidance and is facing a moderately tough Q3 comparable. The most important factors for Q3 2026 are the realization of duty drawback benefits, continued moderation in cigarette volume declines, the national rollout and performance of on! PLUS (including new strengths/flavors), and the impact of Cowboy Cut and Basic on portfolio mix and margins. Macro headwinds and regulatory developments remain key watchpoints.
